Positive results from Supernus Pharmaceuticals' SPN 810 Phase IIa trial for ADHD

Supernus Pharmaceuticals Inc., today announced that its Phase IIa U.S. clinical trial for SPN 810 in children with ADHD and persistent serious conduct problems met the primary endpoints of safety and tolerability, as well as showed statistically significant reduction versus baseline in conduct problems across all doses. The trial was initiated in 2009 and was a proof-of-concept, open-label study in children 6 to 12 years of age, assigned to one of four doses over a six-week treatment period, after 2-5 weeks' titration.

“The product showed reductions of 32% at the lowest tested dose and 55% at the highest tested dose in persistent serious conduct problems with aggression as a key feature”

“The product showed reductions of 32% at the lowest tested dose and 55% at the highest tested dose in persistent serious conduct problems with aggression as a key feature,” said Dr. Robert Findling, MD, the lead investigator for the study. “This is a clinically meaningful and very encouraging set of data. Serious conduct problems are quite prevalent in children with ADHD and there are currently no approved treatments for this unmet medical need.” Results were measured by the conduct problem subscale of the Nisonger Child Behavioral Rating Form (NCBRF).

“We are very excited about these positive results and the future development of SPN 810. The product is one of several programs in our emerging ADHD portfolio,” said Jack Khattar, Supernus President and CEO.

Source Supernus Pharmaceuticals, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New molecular portrait of KRAS in pancreatic cancer may guide better treatments